

# A Clinical, Molecular Genetic and Coagulation study in patients with Klippel-Trenaunay Syndrome and related entities

Published: 25-10-2011

Last updated: 28-04-2024

Detection of mutations in AKT1 in patients with KTS

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Blood and lymphatic system disorders congenital
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON35243

### Source

ToetsingOnline

### Brief title

Klippel-Trenaunay syndrome

### Condition

- Blood and lymphatic system disorders congenital

### Synonym

Klippel-Trenaunay syndrome

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Etiology, Klippel-Trenaunay syndrome, Molecular analysis

## Outcome measures

### Primary outcome

Detection of AKT1 gene mutations

### Secondary outcome

none

## Study description

### Background summary

Klippel-Trenaunay syndrome (KTS) is a congenital malformation syndrome characterised by combinations of vascular malformations (capillary, venous, lymphatic malformations), and localized disturbed growth of bone and soft tissues. Clinical presentation varies extensively. Occurrence is usually sporadic. The recognition of KTS is important because of its possible thrombotic complications. The pathogenesis of KTS is still unclear.

In an earlier part of the present study the clinical characteristics of 100 persons with KTS have been studied, radiological studies of blood vessels have been performed, and coagulation studies performed in a subset of patients. Molecular analysis was done in all patients and included a large set of genes involved in growth and blood vessel formation. No significant abnormality has been found.

Recently mutations have been found in AKT1 in patients with Proteus syndrome [Biesecker et al, N Engl J Med, in the press]. Proteus syndrome resembles KTS to a great extent both in tissues involved and distribution of manifestations; the difference is that Proteus syndrome patients are more severely affected. AKT1 is known to be involved in colon cancer and several other cancers in case of loss-of-function mutations. In Proteus syndrome gain-of-function mutations have been found. Importantly the mutations were not detectable in lymphocytes but only in other tissues.

### Study objective

Detection of mutations in AKT1 in patients with KTS

## Study design

The study will be performed in two steps:

- first, in 5 adult patients buccal swabs and skin biopsies will be studied for mutations. Patients are already participating in the earlier part of the study
- the second step depends on the results of the first step: if mutations will be detectable both in buccal tissue and fibroblasts, a series of 25 patients will be investigated using buccal swabs only. If mutations will be detectable only in fibroblasts, a series of 25 patients will be investigated using skin biopsies. Blood samples of all participating patients are already available and will be studied for mutations as well. All patients are already participating in the earlier part of the study.

## Study burden and risks

buccal swabs: no risk

skin biopsy: very limited risk for infection and keloid formation. No pain if biopsy is performed under local anaesthesia. Only the formation of a scar of 3mm in diameter located at the inner part of the lower arm is a permanent sequella. As the benefit for the group of findings genes is considerable, and possibly even the patients themselves may have benefit of the results of the biopsy if pharmacogenomics allows more directed therapy, we consider it acceptable to perform a skin biopsy in a small series of patients.

## Contacts

### Public

Acadisch Medisch Centrum

Meibergdreef 9  
1105 AZ Amsterdam  
NL

### Scientific

Acadisch Medisch Centrum

Meibergdreef 9  
1105 AZ Amsterdam  
NL

## Trial sites

## Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

## Inclusion criteria

Diagnosis Klippel-Trenaunay syndrome

Age >18yr

## Exclusion criteria

Unreliable diagnosis

Age<18yr

## Study design

### Design

**Study type:** Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

### Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 01-09-2011

Enrollment: 30

Type: Actual

## Ethics review

Approved WMO

Application type:

First submission

Review commission:

METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL37695.018.11